This is a Validated Antibody Database (VAD) review about human S100A7, based on 7 published articles (read how Labome selects the articles), using S100A7 antibody in all methods. It is aimed to help Labome visitors find the most suited S100A7 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
S100A7 synonym: PSOR1; S100A7c; protein S100-A7; psoriasin 1

Santa Cruz Biotechnology
mouse monoclonal (47C1068)
  • western blot; human; 1:1000; loading ...; fig 1
Santa Cruz Biotechnology S100A7 antibody (SantaCruz, 47C1068) was used in western blot on human samples at 1:1000 (fig 1). Proteomes (2017) ncbi
mouse monoclonal (H-8)
  • western blot; human; 1:100; loading ...; fig 2d
Santa Cruz Biotechnology S100A7 antibody (Santa Cruz Biotechnology, sc-377084) was used in western blot on human samples at 1:100 (fig 2d). Breast Cancer Res (2017) ncbi
mouse monoclonal (47C1068)
  • western blot; human; loading ...; fig 3g
Santa Cruz Biotechnology S100A7 antibody (Santa, sc52948) was used in western blot on human samples (fig 3g). Cancer Res (2016) ncbi
mouse monoclonal (47C1068)
  • immunohistochemistry - paraffin section; human; 1:500; fig st1
Santa Cruz Biotechnology S100A7 antibody (Santa Cruz, sc-52948) was used in immunohistochemistry - paraffin section on human samples at 1:500 (fig st1). Oncogenesis (2015) ncbi
mouse monoclonal (47C1068)
  • immunohistochemistry - paraffin section; human; 1:500
Santa Cruz Biotechnology S100A7 antibody (Santa Cruz Biotechnology, sc-52948) was used in immunohistochemistry - paraffin section on human samples at 1:500. Int J Cancer (2014) ncbi
Novus Biologicals
mouse monoclonal (47C1068)
  • immunocytochemistry; human; loading ...; fig 1e
  • western blot; human; loading ...; fig 1f
In order to explore the role of the S100A7 in oral squamous cell carcinoma, Novus Biologicals S100A7 antibody (Imgenex, NBP2-24911) was used in immunocytochemistry on human samples (fig 1e) and in western blot on human samples (fig 1f). Cancer Gene Ther (2016) ncbi
mouse monoclonal (47C1068)
  • immunohistochemistry; human; 1:50; fig 4
Novus Biologicals S100A7 antibody (Clinisciences, IMG-409A) was used in immunohistochemistry on human samples at 1:50 (fig 4). PLoS ONE (2014) ncbi
LifeSpan Biosciences
mouse monoclonal (47C1068)
  • immunohistochemistry; human; 1:3000; loading ...; fig 4e
LifeSpan Biosciences S100A7 antibody (LifeSpan BioSciences, 47C1068) was used in immunohistochemistry on human samples at 1:3000 (fig 4e). Breast Cancer Res (2017) ncbi
Articles Reviewed
  1. Pucci Minafra I, Di Cara G, Musso R, Cancemi P, Albanese N, Roz E, et al. Retrospective Proteomic Screening of 100 Breast Cancer Tissues. Proteomes. 2017;5: pubmed publisher
  2. Sakurai M, Miki Y, Takagi K, Suzuki T, Ishida T, Ohuchi N, et al. Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment. Breast Cancer Res. 2017;19:70 pubmed publisher
  3. Dey K, Bharti R, Dey G, Pal I, Rajesh Y, Chavan S, et al. S100A7 has an oncogenic role in oral squamous cell carcinoma by activating p38/MAPK and RAB2A signaling pathway. Cancer Gene Ther. 2016;23:382-391 pubmed publisher
  4. Eichten A, Su J, Adler A, Zhang L, Ioffe E, Parveen A, et al. Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade. Cancer Res. 2016;76:2327-39 pubmed publisher
  5. Chauhan S, Kaur J, Kumar M, Matta A, Srivastava G, Alyass A, et al. Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer. Oncogenesis. 2015;4:e147 pubmed publisher
  6. Rabeony H, Petit Paris I, Garnier J, Barrault C, Pedretti N, Guilloteau K, et al. Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1?, TNF? and oncostatin M. PLoS ONE. 2014;9:e101937 pubmed publisher
  7. Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, et al. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Int J Cancer. 2014;134:1379-88 pubmed publisher